Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.

Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.

Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late ...

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big ...

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment.

The stock jumps after a melanoma treatment has success in a late-stage trial. One analyst says annual sales could hit $3 ...

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the ...

Moderna shares fell sharply despite positive melanoma trial results as Jefferies modeled $54 billion in peak sales for its ...

The biggest positive for Moderna, Inc. (NASDAQ:MRNA) is that Intismeran could become the product that changes the company’s ...